Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab

Ollin Biosciences has announced positive topline results from its randomized, head-to-head phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo).

The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD). All patients initially received 3 monthly doses of either OLN324 2 mg, OLN324 4 mg, or faricimab 6 mg and were evaluated at weeks 1, 4, 8, 12, 16, and 20.

OLN324 is a VEGF/Ang2 bispecific antibody engineered with “substantially higher Ang2 potency relative to faricimab, increased molar dosing relative to both faricimab and aflibercept (including Eylea HD), and a smaller protein format,” according to the company.

Results showed that OLN324 demonstrated both faster and greater retinal drying than faricimab in patients with DME. Patients treated with OLN324 4 mg experienced mean improvements in retinal drying that were approximately 75% greater than faricimab at week 1 (–79 µm vs –45 µm mean change in central subfield thickness [CST], respectively) and approximately 50% greater at week 12 (–180 µm vs –121 µm). Additionally, according to the company, nearly 90% of patients treated with OLN324 4 mg achieved an absence of DME at week 12, defined as CST < 325 µm, compared with 57% of patients treated with faricimab.

Lei Qian, MD, PhD, chief R&D officer, general biomedicine at Innovent Biologics, collaborators in the development of OLN324, commented on the results in a press release.

“We are excited about the progress of OLN324 (IBI324), driven forward by our partner Ollin—especially the successful results of the JADE phase 1b trial in head-to-head comparison with faricimab. As a next-generation VEGF/Ang-2 bispecific antibody, OLN324 holds the potential to deliver differentiated clinical value for patients with retinal diseases. We look forward to continuing our close collaboration with Ollin to accelerate the global development of this best-in-disease drug,” said Qian.

Arshad M. Khanani, MD, MA, FASRS, managing partner and director of clinical research at Sierra Eye Associates, JADE study investigator, and Ollin scientific advisory board member, added, “The difference in speed and extent of retinal drying observed with OLN324 vs faricimab, the highest bar comparator in DME, is compelling and clinically significant. In real-world practice, this best-in-disease outcome could lead to broad utility for OLN324 across all the major retinal diseases.”

All treatment groups in the trial demonstrated equivalent anatomic outcomes in patients with wAMD, with rapid improvements in OCT mean CST as early as week 1, which were sustained through week 12. Patients across all treatment groups experienced “rapid and sustained mean gains in BCVA [best corrected visual acuity] with numerically greater improvements at week 12” with OLN324 than with faricimab in both DME and wAMD.

Reference

Ollin Biosciences announces positive topline data with superior outcomes from a randomized head-to-head study of OLN324 compared to faricimab (Vabysmo) in diabetic macular edema and wet age-related macular degeneration. News release. Ollin Biosciences, Inc. January 8, 2026. Accessed January 9, 2026. https://ollin.bio/press-releases/ollin-biosciences-announces-positive-topline-data-with-superior-outcomes-from-a-randomized-head-to-head-study-of-oln324-compared-to-faricimab-vabysmo-in-diabetic-macular-edema-and-wet-age-rela/